Mylan's New Patents Will Significantly Enhance Value of EMSAMPITTSBURGH--(BUSINESS WIRE)--March 31, 2004--Mylan Laboratories Inc. (NYSE: MYL) announced today that its subsidiary Mylan Technologies Inc. (MTI) has received notices of allowance from the U.S. Patent and Trademark Office for two patents. These patents when issued will contain claims with respect to the transdermal administration of selegiline and other potential drug products.

MTI granted Somerset Pharmaceuticals Inc., which is jointly owned by Mylan and Watson Pharmaceuticals, an exclusive license to the patents with respect to the transdermal delivery of selegiline, the active ingredient in Somerset's EMSAM^™.

MTI retains the rights to the patented technology with respect to any other compounds, which can be formulated for transdermal delivery.

Mylan Vice Chairman and CEO, Robert J. Coury, stated, "The allowance of these two patents is an important milestone with respect to EMSAM, which is currently under FDA review. These patents significantly enhance the value of the EMSAM opportunity and provide us with a much clearer picture of the potential market for EMSAM, not only at launch, but for years to come."

EMSAM incorporates selegiline into a pressure sensitive adhesive formulation for the transdermal delivery of therapeutically effective amounts of the drug. Somerset is currently engaged in active discussions with a potential licensee who would market and distribute the product.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

This press release includes statements that constitute "forward-looking statements", including with regard to the issuance of MTI's patents, the enhanced value of EMSAM, the potential EMSAM market and the status of third-party discussions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the effects of vigorous competition on commercial acceptance of the Company's products; a delay in or cessation of third-party discussions; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    CONTACT: Mylan Laboratories Inc.
             Kris King, 724-514-1800

    SOURCE: Mylan Laboratories Inc.